Ipca Labs gets 3 USFDA observations for Silvassa unit

In a regulatory filing to BSE, Ipca Laboratories said the USFDA had conducted the inspection of its formulations manufacturing unit situated at Piparia (Silvassa) from August 19 - 23.

New Delhi: Drug firm Ipca Laboratories on Saturday said the US Food and Drug Administration (FDA) has conducted an inspection of its formulations manufacturing unit in Silvassa and issued three observations.

In a regulatory filing to BSE, Ipca Laboratories said the USFDA had conducted the inspection of its formulations manufacturing unit situated at Piparia (Silvassa) from August 19 - 23.

Also Read: Ipca Labs subsidiary acquires 80% stake in Bayshore Pharmaceuticals for USD 10.28 mn

"At the conclusion of the inspection, the US FDA issued a Form 483 with 3 (three) observations. The company shall be submitting its comprehensive response on these observations to the US FDA within the stipulated time frame," it added.

Read Also: Ipca Labs to acquire Ramdev Chemical for Rs 108 crore

The company said it is committed to address these observations promptly.

The US health regulator issues observations by means of Form 483 notifying the company's management of objectionable conditions at the facility inspected.

Read Also: Ban in US market due to change in a drug shortage situation: Ipca Labs